Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Pulmonary Function Tests01:25

Pulmonary Function Tests

Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prospective observational pilot study assessing childhood asthma control in areas with increased urban environmental greenery.

BMC pulmonary medicine·2026
Same author

Improved Lung Function with Home Oscillation and Lung Expansion Therapy in Children: A Case Series.

Pediatric allergy, immunology, and pulmonology·2025
Same author

Changes in Respiratory Care Use During the COVID-19 Pandemic in a Pediatric Long-Term Care Facility.

Pediatric allergy, immunology, and pulmonology·2025
Same author

Pharmaceutical Therapies for Pediatric Respiratory Disease: Setbacks and Progress in 2024.

Pediatric allergy, immunology, and pulmonology·2024
Same author

Artificial Intelligence in Pediatric Respiratory Diseases: Current Status and Future Promises.

Pediatric allergy, immunology, and pulmonology·2024
Same author

Impulse Oscillometry: Where Are We Now?

Pediatric allergy, immunology, and pulmonology·2023
Same journal

Postural Influence on Ventilation Efficiency and Relationship With Oxygen-Enhanced MRI in Cystic Fibrosis.

Pediatric pulmonology·2026
Same journal

Home Non-Invasive Ventilation as an Alternative to Tracheostomy in Infants With Moderate-to-Severe Bronchopulmonary Dysplasia: A Retrospective Cohort Study.

Pediatric pulmonology·2026
Same journal

Perspective of the European Cystic Fibrosis Society on Improving Global Cystic Fibrosis Care.

Pediatric pulmonology·2026
Same journal

Non-Linear Dysanaptic Lung Growth in Patients With Post-Infectious Bronchiolitis Obliterans.

Pediatric pulmonology·2026
Same journal

Safety of Less Invasive Surfactant Administration in Preterm Infants: A Meta-Analysis.

Pediatric pulmonology·2026
Same journal

Early Oxygenation Trajectory and Noninvasive Ventilation Failure in Non-Immunocompromised Children With Pediatric ARDS.

Pediatric pulmonology·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Lung function changes in asthmatic children treated with HFA-BDP.

Nemr Eid1, Ronald Morton

  • 1Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky 40202, USA. nseid@louisville.edu

Pediatric Pulmonology
|April 6, 2011
PubMed
Summary
This summary is machine-generated.

Switching to hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) significantly improved lung function in children with persistent asthma. This extrafine aerosol formulation enhanced airflow without worsening asthma symptoms, supporting its use for better asthma control.

More Related Videos

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
06:11

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Published on: February 9, 2022

Related Experiment Videos

Last Updated: Jun 3, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults
06:11

Employing the Forced Oscillation Technique for the Assessment of Respiratory Mechanics in Adults

Published on: February 9, 2022

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Asthma guidelines emphasize achieving normal lung function for optimal asthma control.
  • Children with persistent asthma often exhibit reduced peripheral airway function.
  • Conventional inhaled corticosteroids (ICS) are standard treatment, but alternative formulations may offer benefits.

Purpose of the Study:

  • To evaluate the efficacy of an extrafine aerosol formulation of beclomethasone dipropionate (HFA-BDP) in improving lung function in children with persistent asthma.
  • To assess changes in peripheral airway function after switching from conventional ICS to HFA-BDP.
  • To determine if HFA-BDP improves airflow without compromising asthma control.

Main Methods:

  • A study involving 20 children (7 girls, 13 boys) with stable, moderate persistent asthma and reduced FEF(25-75).
  • Children were switched from conventional ICS to HFA-BDP, with other medications remaining unchanged.
  • Lung function (FEF(25-75), FEV(1)) and clinical status were reassessed at least 3 weeks post-intervention.

Main Results:

  • Significant improvement in mean FEF(25-75) from 50.75% to 68.85% predicted (P < 0.001).
  • Significant increase in FEV(1) from 84.6% to 93.8% predicted (P = 0.001).
  • No significant changes in asthma symptoms were observed during the study period.

Conclusions:

  • Hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) significantly enhances airflow in both large and peripheral airways in asthmatic children.
  • The switch to HFA-BDP improves lung function metrics without negatively impacting asthma control.
  • Extrafine aerosol ICS formulations like HFA-BDP represent a valuable therapeutic option for pediatric asthma management.